Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Nov;22(11):1489-1497.
doi: 10.1111/ddg.15511. Epub 2024 Oct 2.

Pegylated interferon-α2a in cutaneous T-cell lymphoma - a multicenter retrospective data analysis with 70 patients

Inga Hansen-Abeck  1 , Glenn Geidel  1 , Finn Abeck  1 , Julian Kött  1 , Rohat Cankaya  2 , Gabor Dobos  2 , Christina Mitteldorf  3 , Jan P Nicolay  4 , Jana D Albrecht  4 , Christian Menzer  5 , Elisabeth Livingstone  6 , Miriam Mengoni  7 , Andreas D Braun  7 , Marion Wobser  8 , Claus-Detlev Klemke  9 , Sabine Tratzmiller  9 , Chalid Assaf  10 , Patrick Terheyden  11 , Kai-Christian Klespe  12 , Stefan W Schneider  1 , Nina Booken  1
Affiliations
Multicenter Study

Pegylated interferon-α2a in cutaneous T-cell lymphoma - a multicenter retrospective data analysis with 70 patients

Inga Hansen-Abeck et al. J Dtsch Dermatol Ges. 2024 Nov.

Abstract

Background: Interferon-alpha is an important therapeutic option for the treatment of the cutaneous T-cell lymphomas (CTCL). Since the approved recombinant interferon-α-2a (IFN-α2a) has no longer been produced since January 2020, pegylated interferon-α2a (pegIFN-α2a) can be used as an alternative treatment, even though it is not approved for the treatment of CTCL. The aim of this multicentre study was to generate comprehensive data on the efficacy and tolerability of pegIFN-α2a in the treatment of CTCL.

Patients and methods: A multicenter retrospective study was conducted with 70 patients with CTCL from twelve German skin centers.

Results: In total, 70 patients were included in the study, with 57.2% male and a mean age of 58.8 ± 14.9 years. Mycosis fungoides was present in 71.4% of cases and Sézary Syndrome in 28.6%. An overall response rate of 55.2% was observed with pegIFNα-2a therapy. In 50% of cases, therapy was discontinued after 63.6 ± 33.5 weeks. The most common reason for discontinuation was adverse events, which occurred in 68.6% of cases and which were classified as severe in 29.2%. Blood count changes, fatigue and liver toxicity occurred most frequently.

Conclusions: Our analysis provides comprehensive data on the efficacy and tolerability of pegIFNα-2a therapy in patients with CTCL. In terms of response rates and side effect profile, pegIFNα-2a appears to be comparable to IFN-α2a therapy.

Keywords: Mycosis fungoides; Sézary Syndrome; cutaneous t‐cell lymphomas; interferon‐alpha; pegylated interferon.

PubMed Disclaimer

References

REFERENCES

    1. Jonak C, Tittes J, Brunner PM, Guenova E. Mycosis fungoides und Sezary‐Syndrom. J Dtsch Dermatol Ges. 2021;19(9):1307‐1335.
    1. Assaf C, Dobos G, Zech IM, et al. Epidemiology of mature T/NK‐cell lymphomas in Germany ‐ A representative cross‐sectional study based on SHI claims data. J Dtsch Dermatol Ges. 2023;21(11):1320‐1327.
    1. Latzka J, Assaf C, Bagot M, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome – Update 2023. Eur J Cancer. 2023;195:113343.
    1. Dippel E, Assaf C, Becker JC, et al. S2k‐Guidelines ‐ Cutaneous lymphomas (ICD10 C82 ‐ C86): Update 2021. J Dtsch Dermatol Ges. 2022;20(4):537‐554.
    1. Bunn PA, Jr., Foon KA, Ihde DC, et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T‐cell lymphomas. Ann Intern Med. 1984;101(4):484‐487.

Publication types

LinkOut - more resources